Cases & evidence
The interview leans on patient stories and a scientific lineage - while openly acknowledging this remains a minority position in oncology.
Patient cases described
Pablo Kelly
Devon, EnglandDiagnosed with an inoperable glioblastoma; declined radiation and chemo in favour of metabolic therapy. Lived ~10 years; the tumour became operable and was surgically debulked four times. Died from a cerebral haemorrhage during a later surgery - not from the tumour itself.
Trudy Dupont
United StatesAn American lawyer with a brain-stem tumour whose case led Seyfried to develop the Glucose Ketone Index. She used metabolic therapy and survived over 10 years. Her volatile blood-sugar readings inspired the glucose-to-ketone ratio.
Andrew Scarborough
EnglandStage-3 brain cancer patient roughly 15 years out, who has practised metabolic therapy so long he can now recognise which metabolic zone he is in from how he feels.
Greek glioblastoma group
GreeceReported strong results keeping glioblastoma patients alive using a calorie-restricted Mediterranean diet (salmon, sardines, olive oil, avocado) plus exercise - showing the approach is not limited to strict carnivore/keto diets.
These are individual anecdotes recounted in the interview, not controlled trials. They are presented as the speaker described them.
The scientific lineage
- Otto Warburg (1920s-40s) - Nobel laureate who first showed cancer cells ferment even with oxygen and proposed damaged respiration as the cause.
- Albert Szent-Györgyi - framed the “oncogenic paradox” of many causes, one unknown mechanism.
- Seyfried’s group at Boston College - revisited Warburg’s work with modern electron microscopy and the nuclear-transfer evidence.
- Christos Chinopoulos (Semmelweis University) - work on the mitochondrial fermentation of glutamine.
- Collaborators - Dominic D’Agostino (hyperbaric oxygen), Joe Maroon (press-pulse), plus students Derek Lee, Josh Fidenbower and others.
The case against mainstream oncology
Seyfried’s central critique is institutional, not personal - he calls most oncologists “good people” trapped in a system that never trained them in the biochemistry of the disease:
- Mainstream care rests on the somatic mutation theory - cancer as a genetic disease - which he argues explains the mutations as effects, not causes.
- New sequencing finds driver mutations in normal, healthy tissue, and “wild-type” cancers with no such mutations.
- The system requires large double-blind phase-3 trials before adopting a protocol, and dietary interventions rarely attract that funding - so clinicians “lack the institutional green light.”
- He is scathing about hospital nutrition advice to “eat whatever you can” - often sugary shakes that, in his view, feed the tumour.
- He reframes cachexia (wasting) as the tumour dissolving muscle for glutamine - arguing therapeutic ketosis produces therapeutic weight loss, distinct from pathological wasting.
“There are 1,700 people a day in this country dying from cancer - 70 an hour - and it gets worse every single year. When are people going to wake up?”
The Copernican analogy
Seyfried compares the entrenched genetic theory to the geocentric model of the solar system - defended for 1,800 years until Copernicus, Kepler and Galileo, and at the cost of martyrs like Giordano Bruno. His claim is that challenging an established power structure, whether a church or an industry, is hazardous - but that the data will eventually force the shift.
The forthcoming paper
The “confidential envelope” at the start of the interview is an embargoed paper Seyfried says is slated as a lead article in Frontiers in Science - presenting the bioenergetic GKI chart and strategy, with a companion version written for “young minds” (ages ~8-14). He also mentions launching a society, MORE (Metabolic Oncology Research and Education), and notes his group’s research is funded by private foundations and philanthropy (e.g. Travis Christofferson’s foundation).
Sources
- Warburg O (1956). On the origin of cancer cells. Science. doi:10.1126/science.123.3191.309
- Elsakka AMA, Bary MA, Abdelzaher E, et al. (2018). Management of Glioblastoma Multiforme in a Patient Treated With Ketogenic Metabolic Therapy and Modified Standard of Care: A 24-Month Follow-Up. Frontiers in Nutrition. doi:10.3389/fnut.2018.00020
- Martincorena I, Roshan A, Gerstung M, et al. (2015). High burden and pervasive positive selection of somatic mutations in normal human skin. Science. doi:10.1126/science.aaa6806
- Chinopoulos C, Seyfried TN (2018). Mitochondrial Substrate-Level Phosphorylation as Energy Source for Glioblastoma: Review and Hypothesis. ASN Neuro. doi:10.1177/1759091418818261